TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A study in obese mice found that tirzepatide, the active drug in Mounjaro and Zepbound, activated brown adipose tissue, which uses energy. The researchers say the result could point to effects beyond reduced food intake, but it does not establish that the same process occurs in people.
A study in obese mice found that tirzepatide, the active drug in Mounjaro and Zepbound, activated brown adipose tissue, which uses energy. The result offers a possible explanation for metabolic effects beyond the drug’s reduction of food intake, but the researchers say it remains unknown whether the same effect occurs in humans.
Led by Marion Peyrou of the University of Barcelona and collaborating research institutes, the team studied mice made obese by a high-fat diet. They compared mice treated with tirzepatide with untreated mice given the same amount of food. Matching food intake helped the researchers examine drug effects that could not be explained simply by the treated animals eating less.
The analysis found activation of brown adipose tissue, or brown fat. Unlike white fat, which mainly stores energy, brown fat uses energy. The researchers also reported production of batokines, signaling molecules made by brown fat that they described as beneficial for metabolism. The study summary does not establish the size or durability of these effects in people.
Peyrou said brown fat uses glucose and fat, and that its activity could contribute to tirzepatide’s effects on body weight and metabolic measures. Those are the researchers’ interpretation of the mouse findings; the experiment does not show that brown-fat activation explains the drug’s clinical effects in humans.
A Possible Effect Beyond Appetite
Tirzepatide targets receptors for GIP and GLP-1. Its effects on food intake are a major part of how it promotes weight loss, but the mouse experiment points to another possible pathway: increased energy use by brown fat. If a comparable effect were demonstrated in people, it could help researchers understand how the drug affects metabolism and why responses may differ among patients.
The finding may also inform research into obesity treatments that affect more than appetite. The researchers say brown-fat activation has been considered as a potential treatment approach, while earlier attempts using drugs have often been limited by unwanted effects, including effects on the heart. Their report says tirzepatide did not produce those negative effects in this work and notes its cardiovascular benefits; the supplied study account does not provide detailed safety measurements from the mouse experiment to assess that comparison.
How the Mouse Comparison Worked
Tirzepatide is used for weight management in adults with obesity or overweight with related conditions, and for type 2 diabetes, according to the report. Mounjaro is a brand name for tirzepatide; the headline also refers to Zepbound, another brand name for the same active drug. The drug acts on receptors for two hormones, GIP and GLP-1, rather than just one.
To separate potential direct drug effects from the consequences of eating less, the researchers used a food-matched comparison: untreated mice received the same amount of food as treated mice. The team examined different fat deposits because, as the report explains, this detailed tissue analysis cannot readily be carried out in humans. The findings were published in a study covered by ScienceDaily on September 25, 2026.
“As this is a study conducted on mice, we must be cautious, as there may be significant differences between species in terms of metabolism regulation, adipose tissue distribution and response to drugs.”
— Marion Peyrou
Human Effects Still Need Study
The reported experiment was conducted in mice, not people. It does not confirm that tirzepatide activates human brown fat, how large any such effect might be, or whether it contributes meaningfully to weight loss or changes in blood glucose and fat levels. The report also does not specify the study’s sample size, duration, or detailed measurements, limiting what can be assessed from the available account.
Differences between mouse and human metabolism, fat distribution and drug responses could affect whether the result translates. The researchers say clinical evidence is needed; which patient groups, if any, might benefit more from this mechanism has not been established.
Clinical Evidence Is the Next Step
The next step identified by the researchers is to examine how these drugs affect fat tissue in humans. Clinical studies would need to establish whether brown-fat activation occurs in patients and how it relates to metabolic outcomes. Until such evidence is available, the mouse result is a clue about a possible mechanism, not proof of how tirzepatide works in people.
Key Questions
What did the study find?
Researchers reported that tirzepatide activated brown adipose tissue in obese mice. They compared treated animals with untreated mice given the same amount of food.
Does this prove Zepbound activates brown fat in people?
No. The work described was conducted in mice. The researchers say clinical evidence is needed to determine whether the same effect occurs in humans.
What is brown fat?
Brown adipose tissue uses energy, unlike white fat, which mainly stores it. The study examined whether tirzepatide changed brown-fat activity independently of differences in food intake.
Is brown fat the main reason tirzepatide causes weight loss?
The study does not establish that. Tirzepatide reduces food intake, and the researchers propose that brown-fat activity may be an additional metabolic effect. Its contribution to weight loss in people remains unclear.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
